ThomasCarlKrivakMD
Obstetrics & Gynecology • Pittsburgh, PAGynecologic Oncology
Assistant Professor, Ob/Gyn & Reproductive Science, University of Pittsburgh School of Medicine
Dr. Krivak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4815 Liberty Ave
Ste GR30
Pittsburgh, PA 15224Phone+1 412-578-1116Fax+1 412-578-1116
Education & Training
David Grant Medical CenterResidency, Obstetrics and Gynecology, 1994 - 1998
Ohio State University College of MedicineClass of 1994
Certifications & Licensure
CA State Medical License 1997 - Present
PA State Medical License 2005 - 2024
WV State Medical License 2014 - 2016
DC State Medical License 2001 - 2006- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Most Compassionate Doctor American Registry
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer Start of enrollment: 2008 Dec 01
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Join now to see all
Publications & Presentations
PubMed
- 57 citationsRelationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cis...Thomas C. Krivak, Kathleen M. Darcy, Chunqiao Tian, Deborah K. Armstrong, Bora E. Baysal
Journal of Clinical Oncology. 2008-07-20 - 39 citationsChemosensitivity testing with ChemoFx and overall survival in primary ovarian cancerThomas J. Herzog, Thomas C. Krivak, Amanda N. Fader, Robert L. Coleman
American Journal of Obstetrics and Gynecology. 2010-07-01 - 23 citationsDual-console robotic surgery compared to laparoscopic surgery with respect to surgical outcomes in a gynecologic oncology fellowship program.Ashlee L. Smith, Thomas C. Krivak, E. Scott, Jose Alejandro Rauh-Hain, Paniti Sukumvanich
Gynecologic Oncology. 2012-09-01
Journal Articles
- Survival Disparities in Vulvar Cancer Patients in Commission on Cancer®-Accredited FacilitiesNicole B Gaulin, Jamie L Lesnock, Scott D Richard, Thomas C Krivak, Eirwen M Miller, Yovanni Casablanca, Gynecologic Oncology
Press Mentions
He Cured Her from Ovarian Cancer. She Thanked Him with More Than $700,000 to Help OthersJanuary 9th, 2022
Immunotherapy Could Be Game Changer in Cancer TreatmentApril 22nd, 2019- ‘Chemo Bath’ Being Used to Target Difficult to Treat Cancers in AbdomenMay 31st, 2018
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
